High-Output Fistula

 

 Buy Article Permissions and Reprints

Despite improvements in healthcare delivery, mortality rates for high-output fistulae remain unchanged. The pathophysiology and causes of fistulae are reviewed in this article. An overview of the diagnostic procedures to delineate fistulae and underlying bowel disease together with their complications is included. Management of high-output fistulae consists of assessment and stabilization of patients, followed by conservative management by a multidisciplinary team until spontaneous or surgical closure of fistulae.

REFERENCES

• 1 Edmunds Jr L H, Williams G M, Welch C E. External fistulas arising from the gastro-intestinal tract.  Ann Surg. 1960;  152 445-471
  CrossrefPubMedGoogle Scholar
• 2 Rocchio M A, Cha C J, Haas K F, Randall H T. Use of chemically defined diets in the management of patients with high output gastrointestinal cutaneous fistulas.  Am J Surg. 1974;  127 148-156
  CrossrefPubMedGoogle Scholar
• 3 Deitel M. Nutritional management of external gastrointestinal fistulas.  Can J Surg. 1976;  19 505-509
  PubMedGoogle Scholar
• 4 Sitges-Serra A, Jaurrieta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery.  Br J Surg. 1982;  69 147-150
  CrossrefPubMedGoogle Scholar
• 5 McIntyre P B, Ritchie J K, Hawley P R. Management of enterocutaneous fistulas: a review of 132 cases.  Br J Surg. 1984;  71 293-296
  PubMedGoogle Scholar
• 6 Athanassiades S, Notis P, Tountas C. Fistulas of the gastrointestinal tract. Experience with eighty-one cases.  Am J Surg. 1975;  130 26-28
  CrossrefPubMedGoogle Scholar
• 7 Chamberlain R S, Kaufman H L, Danforth D N. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment.  Am Surg. 1998;  64 1204-1211
  PubMedGoogle Scholar
• 8 Feldman M, Goldschmiedt M. Gastric HCO₃-secretion: relationship with Na⁺ secretion and effect of acetazolamide in humans.  Am J Physiol. 1991;  261(2 Pt 1) G320-G326
  PubMedGoogle Scholar
• 9 Read N W, Cooper K, Fordtran J S. Effect of modified sham feeding on jejunal transport and pancreatic and biliary secretion in man.  Am J Physiol. 1978;  234 E417-E420
  PubMedGoogle Scholar
• 10 Kidd M, Modlin I M, Tang L H. Gastrin and the enterochromaffin-like cell: an acid update.  Dig Surg. 1998;  15 209-217
  CrossrefPubMedGoogle Scholar
• 11 Drucker D J, Erlich P, Asa S L, Brubaker P L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2.  Proc Natl Acad Sci USA. 1996;  93 7911-7916
  CrossrefPubMedGoogle Scholar
• 12 Jeppesen P B, Hartmann B, Thulesen J et al.. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.  Gastroenterology. 2001;  120 806-815
  CrossrefPubMedGoogle Scholar
• 13 Alexander E S, Weinberg S, Clark R A, Belkin R D. Fistulas and sinus tracts: radiographic evaluation, management, and outcome.  Gastrointest Radiol. 1982;  7 135-140
  CrossrefPubMedGoogle Scholar
• 14 Cresci G A, Martindale R G. Metabolic and nutritional management of a patient with multiple enterocutaneous fistulas.  Nutrition. 1997;  13 446-448
  CrossrefPubMedGoogle Scholar
• 15 Gasche C, Moser G, Turetschek K, Schober E, Moeschl P, Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease.  Gut. 1999;  44 112-117
  CrossrefPubMedGoogle Scholar
• 16 Maconi G, Parente F, Porro G B. Hydrogen peroxide enhanced ultrasound-fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease.  Gut. 1999;  45 874-878
  CrossrefPubMedGoogle Scholar
• 17 Maconi G, Sampietro G M, Parente F et al.. Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study.  Am J Gastroenterol. 2003;  98 1545-1555
  CrossrefPubMedGoogle Scholar
• 18 Orel S G, Rubesin S E, Jones B, Fishman E K, Bayless T M, Siegelman S S. Computed tomography vs barium studies in the acutely symptomatic patient with Crohn disease.  J Comput Assist Tomogr. 1987;  11 1009-1016
  PubMedGoogle Scholar
• 19 Jobling C, Halligan S, Bartram C. The use of non-ionic water-soluble contrast agents for small bowel follow-through examination.  Eur Radiol. 1999;  9 706-710
  CrossrefPubMedGoogle Scholar
• 20 Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs H J. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison.  Eur Radiol. 2002;  12 1416-1422
  CrossrefPubMedGoogle Scholar
• 21 Rieber A, Nussle K, Reinshagen M, Brambs H J, Gabelmann A. MRI of the abdomen with positive oral contrast agents for the diagnosis of inflammatory small bowel disease.  Abdom Imaging. 2002;  27 394-399
  CrossrefPubMedGoogle Scholar
• 22 Koelbel G, Schmiedl U, Majer M C et al.. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging.  AJR Am J Roentgenol. 1989;  152 999-1003
  PubMedGoogle Scholar
• 23 Bell S J, Halligan S, Windsor A C, Williams A B, Wiesel P, Kamm M A. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging.  Aliment Pharmacol Ther. 2003;  17 387-393
  CrossrefPubMedGoogle Scholar
• 24 Dombrowski S R, Mirtallo J M. Drug therapy and nutritional management of patients with gastrointestinal fistulas.  Clin Pharm. 1984;  3 264-272
  PubMedGoogle Scholar
• 25 Bruley des Varennes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche J P. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.  Aliment Pharmacol Ther. 1994;  8 309-314
  PubMedGoogle Scholar
• 26 Londong W, Londong V, Cederberg C, Steffen H. Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release.  Gastroenterology. 1983;  85 1373-1378
  PubMedGoogle Scholar
• 27 Katz P O, Hatlebakk J G, Castell D O. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.  Aliment Pharmacol Ther. 2000;  14 709-714
  CrossrefPubMedGoogle Scholar
• 28 Deitel M. Nutritional management of external gastrointestinal fistulas.  Can J Surg. 1976;  19 505-509
  PubMedGoogle Scholar
• 29 Rose D, Yarborough M F, Canizaro P C, Lowry S F. One hundred and fourteen fistulas of the gastrointestinal tract treated with total parenteral nutrition.  Surg Gynecol Obstet. 1986;  163 345-350
  PubMedGoogle Scholar
• 30 Rocchio M A, Cha C J, Haas K F, Randall H T. Use of chemically defined diets in the management of patients with high output gastrointestinal cutaneous fistulas.  Am J Surg. 1974;  127 148-156
  CrossrefPubMedGoogle Scholar
• 31 Levy E, Frileux P, Cugnenc P H, Honiger J, Ollivier J M, Parc R. High-output external fistulae of the small bowel: management with continuous enteral nutrition.  Br J Surg. 1989;  76 676-679
  PubMedGoogle Scholar
• 32 Sitges-Serra A, Jaurrieta E, Sitges-Creus A. Management of postoperative enterocutaneous fistulas: the roles of parenteral nutrition and surgery.  Br J Surg. 1982;  69 147-150
  CrossrefPubMedGoogle Scholar
• 33 Zera R T, Bubrick M P, Sternquist J C, Hitchcock C R. Enterocutaneous fistulas. Effects of total parenteral nutrition and surgery.  Dis Colon Rectum. 1983;  26 109-112
  PubMedGoogle Scholar
• 34 McIntyre P B, Ritchie J K, Hawley P R. Management of enterocutaneous fistulas: a review of 132 cases.  Br J Surg. 1984;  71 293-296
  PubMedGoogle Scholar
• 35 Wolfe B M, Keltner R M, Willman V L. Intestinal fistula output in regular, elemental, and intravenous alimentation.  Am J Surg. 1972;  124 803-806
  CrossrefPubMedGoogle Scholar
• 36 Chamberlain R S, Kaufman H L, Danforth D N. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment.  Am Surg. 1998;  64 1204-1211
  PubMedGoogle Scholar
• 37 Frost S. Stoma care: managing high-output fistulas.  Nurs Stand. 1991;  5 25-27
  PubMedGoogle Scholar
• 38 Burch J. The nursing care of a patient with enterocutaneous faecal fistulae.  Br J Nurs. 2003;  12 736-740
  PubMedGoogle Scholar
• 39 Lichtenstein G R. Treatment of fistulizing Crohn's disease.  Gastroenterology. 2000;  119 1132-1147
  CrossrefPubMedGoogle Scholar
• 40 Walsh J H. Gastrointestinal hormones. In: Johnson LR Physiology of the Gastrointestinal Tract. New York; Raven Press 1994: 1-128
  Google Scholar
• 41 Pederzoli P, Bassi C, Falconi M, Albrigo R, Vantini I, Micciolo R. Conservative treatment of external pancreatic fistulas with parenteral nutrition alone or in combination with continuous intravenous infusion of somatostatin, glucagon or calcitonin.  Surg Gynecol Obstet. 1986;  163 428-432
  PubMedGoogle Scholar
• 42 Torres A J, Landa J I, Moreno-Azcoita M et al.. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial.  Arch Surg. 1992;  127 97-99
  CrossrefPubMedGoogle Scholar
• 43 Planas M, Porta I, Angles R, Baena J A, Serra J, Padro J B. [Somatostatin and/or total parenteral nutrition for the treatment of intestinal fistulas].  Rev Esp Enferm Dig. 1990;  78 345-347
  PubMedGoogle Scholar
• 44 Torres A J, Landa J I, Moreno-Azcoita M et al.. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial.  Arch Surg. 1992;  127(1) 97-99
  CrossrefPubMedGoogle Scholar
• 45 Nubiola-Calonge P, Badia J M, Sancho J, Gil M J, Segura M, Sitges-Serra A. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output.  Lancet. 1987;  2 672-674
  PubMedGoogle Scholar
• 46 Scott N A, Finnegan S, Irving M H. Octreotide and gastrointestinal fistulae.  Digestion. 1990;  45(Suppl 1) XS66-70 , discussion 70-71
  PubMedGoogle Scholar
• 47 Sancho J J, di Costanzo J, Nubiola P et al.. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula.  Br J Surg. 1995;  82 638-641
  CrossrefPubMedGoogle Scholar
• 48 Hernandez-Aranda J C, Gallo-Chico B, Flores-Ramirez L A, Avalos-Huante R, Magos-Vazquez F J, Ramirez-Barba E J. [Treatment of enterocutaneous fistula with or without octreotide and parenteral nutrition].  Nutr Hosp. 1996;  11 226-229
  PubMedGoogle Scholar
• 49 Hesse U, Ysebaert D, de Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data.  Gut. 2001;  49(Suppl 4) iv11-iv21
  CrossrefPubMedGoogle Scholar
• 50 di Costanzo J, Cano N, Martin J et al.. Treatment of external gastrointestinal fistulas by a combination of total parenteral nutrition and somatostatin.  JPEN J Parenter Enteral Nutr. 1987;  11 465-470
  PubMedGoogle Scholar
• 51 Ysebaert D, Van Hee R, Hubens G, Vaneerdeweg W, Eyskens E. Management of digestive fistulas.  Scand J Gastroenterol Suppl. 1994;  207 42-44
  PubMedGoogle Scholar
• 52 Hild P, Dobroschke J, Henneking K, Rieck B. Treatment of enterocutaneous fistulas with somatostatin.  Lancet. 1986;  2 626
  PubMedGoogle Scholar
• 53 Nubiola P, Badia J M, Martinez-Rodenas F et al.. Treatment of 27 postoperative enterocutaneous fistulas with the long half-life somatostatin analogue SMS 201-995.  Ann Surg. 1989;  210 56-58
  CrossrefPubMedGoogle Scholar
• 54 Barnes S M, Kontny B G, Prinz R A. Somatostatin analog treatment of pancreatic fistulas.  Int J Pancreatol. 1993;  14 181-188
  PubMedGoogle Scholar
• 55 O'Keefe S J, Haymond M W, Bennet W M, Oswald B, Nelson D K, Shorter R G. Long-acting somatostatin analogue therapy and protein metabolism in patients with jejunostomies.  Gastroenterology. 1994;  107 379-388
  PubMedGoogle Scholar
• 56 Berry S M, Fischer J E. Classification and pathophysiology of enterocutaneous fistulas.  Surg Clin North Am. 1996;  76 1009-1018
  CrossrefPubMedGoogle Scholar
• 57 Athanassiades S, Notis P, Tountas C. Fistulas of the gastrointestinal tract. Experience with eighty-one cases.  Am J Surg. 1975;  130 26-28
  CrossrefPubMedGoogle Scholar
• 58 Rabago L R, Ventosa N, Castro J L, Marco J, Herrera N, Gea F. Endoscopic treatment of postoperative fistulas resistant to conservative management using biological fibrin glue.  Endoscopy. 2002;  34 632-638
  Article in Thieme ConnectPubMedGoogle Scholar

Alastair ForbesM.D. 

Department of Medicine, St. Mark's Hospital, Northwick Park, Watford Road, Harrow, Middlesex, HA1 3UJ, United Kingdom

Email: alastair.forbes@imperial.ac.uk